[go: up one dir, main page]

WO2006117534A3 - New use - Google Patents

New use Download PDF

Info

Publication number
WO2006117534A3
WO2006117534A3 PCT/GB2006/001582 GB2006001582W WO2006117534A3 WO 2006117534 A3 WO2006117534 A3 WO 2006117534A3 GB 2006001582 W GB2006001582 W GB 2006001582W WO 2006117534 A3 WO2006117534 A3 WO 2006117534A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
new use
combination
gluccorticosteroid
bronchodilator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/001582
Other languages
French (fr)
Other versions
WO2006117534A2 (en
Inventor
Bertil Lindmark
Anders Thoren
Timothy William Higenbottam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2006117534A2 publication Critical patent/WO2006117534A2/en
Publication of WO2006117534A3 publication Critical patent/WO2006117534A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New Use The invention provides medicaments comprising a combination of a HMG-CoA reductase inhibitor and a drug intervening in the renin-angiotensin system selected from angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors optionally in combination with a bronchodilator and a gluccorticosteroid in the treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD).
PCT/GB2006/001582 2005-04-30 2006-04-28 New use Ceased WO2006117534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0508924.8A GB0508924D0 (en) 2005-04-30 2005-04-30 New use
GB0508924.8 2005-04-30

Publications (2)

Publication Number Publication Date
WO2006117534A2 WO2006117534A2 (en) 2006-11-09
WO2006117534A3 true WO2006117534A3 (en) 2007-01-25

Family

ID=34674198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001582 Ceased WO2006117534A2 (en) 2005-04-30 2006-04-28 New use

Country Status (2)

Country Link
GB (1) GB0508924D0 (en)
WO (1) WO2006117534A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5349302B2 (en) 2006-07-05 2013-11-20 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of HMG-CoA reductase inhibitor and phosphodiesterase 4 inhibitor for the treatment of inflammatory lung disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508665A2 (en) * 1991-04-01 1992-10-14 E.R. SQUIBB & SONS, INC. Use of ACE inhibitors for lowering serum cholesterol
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US20030049314A1 (en) * 2001-08-28 2003-03-13 Liang Matthew H. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040039033A1 (en) * 2001-12-10 2004-02-26 Atwal Karnail S. (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
US20040043991A1 (en) * 2002-08-13 2004-03-04 Picard Joseph Armand Pyrimidinone fused bicyclic metalloproteinase inhibitors
US20050080087A1 (en) * 2003-10-10 2005-04-14 Annapurna Pendri Pyrazole derivatives as cannabinoid receptor modulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
EP0508665A2 (en) * 1991-04-01 1992-10-14 E.R. SQUIBB & SONS, INC. Use of ACE inhibitors for lowering serum cholesterol
US20030049314A1 (en) * 2001-08-28 2003-03-13 Liang Matthew H. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040039033A1 (en) * 2001-12-10 2004-02-26 Atwal Karnail S. (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
US20040043991A1 (en) * 2002-08-13 2004-03-04 Picard Joseph Armand Pyrimidinone fused bicyclic metalloproteinase inhibitors
US20050080087A1 (en) * 2003-10-10 2005-04-14 Annapurna Pendri Pyrazole derivatives as cannabinoid receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CATTANEO AND REMUZZI: "Lipid oxidative stress and the anti-inflammatory properties of statins", J REN NUTR, vol. 15, no. 1, January 2005 (2005-01-01), pages 71 - 76, XP009073911 *

Also Published As

Publication number Publication date
GB0508924D0 (en) 2005-06-08
WO2006117534A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
NO20070651L (en) Compositions of statins with bronchodilators
WO2008049000A3 (en) Combination therapy for pulmonary arterial hypertension
WO2008068217A3 (en) Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
WO2008043561A3 (en) Influenza targets
WO2006120176A3 (en) Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
NO20071446L (en) Endothelin A receptor (ETA) antagonists in combination with phosphodiesterase 5 inhibitors (PDE5) and applications thereof.
WO2007071313A3 (en) Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
IL190201A0 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
WO2006041773A3 (en) Lactam compounds useful as protein kinase inhibitors
MX2009008363A (en) Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist.
EA200900073A1 (en) COMBINATION OF HMG-CoA REDUCTASE INHIBITORS AND PHOSPHODESTERASE 4 INHIBITORS, INTENDED FOR THE TREATMENT OF INFLAMMATIVE LUNG DISEASES
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
EP1773374A4 (en) An agent comprising fgf2 as an effective ingredient for treatment or prevention of asthma and chronic obstructive pulmonary disease
WO2006117534A3 (en) New use
MX2013003816A (en) Novel combinations.
MX2010012019A (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.
WO2006117761A3 (en) Magnesium salts of hmg-coa reductase inhibitors
WO2009139648A3 (en) Methods and compositions for assessment of pulmonary function and disorders
WO2008066770A3 (en) Ace2 activator compounds and methods of use thereof
WO2006086609A3 (en) Inhibitors of tryptase
WO2006041808A8 (en) Tafi inhibitors and their use to treat pulmonary fibrosis
WO2008010008A3 (en) Cardiovascular combinations using rennin-angiotensin inhibitors
EP2323655A4 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06726962

Country of ref document: EP

Kind code of ref document: A2